Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in cystic lung destruction. It predominantly affects women, especially during childbearing years. The term sporadic LAM is used for patients with LAM not associated with tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC. The condition is often misdiagnosed as asthma or chronic obstructive pulmonary disease. The first pneumothorax precedes the diagnosis of LAM in 82% of patients. The consensus clinical definition of LAM includes multiple symptoms : Fatigue, Cough, Haemoptysis, Chest pain, Chylous complications arising from lymphatic obstruction.

  • Chylopericardium.
  • Angiomyolipomas
  • Lymphangioleiomyomatosis

Related Conference of Lymphangioleiomyomatosis

January 27-28, 2020

3rd Global Experts Meeting on Infectious Diseases

Bangkok, Thailand
February 10-11, 2020

2nd Global Experts Meet on STD-AIDS and Infectious Diseases

Sydney, Australia
February 24-25, 2020

7th International Congress on Infectious Diseases

Berlin, Germany
April 27-28, 2020

7th Global Congress on Rare Diseases & Orphan Drug

Istanbul, Turkey
July 22-23, 2020

10th World Congress on Rare Diseases and Orphan Drugs

Barcelona, Spain
August 19-20, 2020

European Summit on HIV, STD and STIs

Milan, Italy
September 28-29, 2020

13th Global Infections Conference

September 28-29, 2020

World Congress on Infectious Diseases and Rare Diseases

Osaka, Japan
October 5-6, 2020

12th Euro-Global Conference on Infectious Diseases

Vienna, Austria
November 25-26, 2020

Intercontinental Conference on Infectious Diseases

Tokyo, Japan

Lymphangioleiomyomatosis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in